GlassScriptPhysician profile
Nakeesha Layne
NPI 1518482918
$1,120.26
in general payments reported to CMS, 2019-2025
15 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.69 · 2022: $99.11 · 2023: $189 · 2024: $392 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $385.00 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $302.90 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $78.20 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $60.35 | 2024 | Qelbree |
| Pfizer INC. | $47.75 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $45.42 | 2025 | Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2021-2025 | Vpriv |
| Glaxosmithkline, LLC. | $30.45 | 2023-2024 | Bexsero |
| Merck Sharp & Dohme LLC | $30.22 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sobi, INC | $21.88 | 2022 | |
| Optinose US, INC. | $20.69 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $18.28 | 2025 | Neffy |
| Abbvie INC. | $17.95 | 2025 | |
| Soleno Therapeutics, INC. | $16.20 | 2025 | Vykat Xr |
| Genentech USA, INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakeesha Layne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.